Eric Venker, President & Immunovant CEO of Roivant Sciences Ltd. (ROIV), sold 185,856 shares of the company's stock on October 20, 2026. The transactions were executed at an average price of $35.09 per share, for a total value of approximately $6.52 million.
This sale follows other recent stock sales by Mr. Venker and other Roivant Sciences insiders. Insider selling can occur for a variety of reasons, including portfolio diversification or to meet tax obligations, and does not necessarily indicate a negative view of the company's future prospects.